Products for Research Use Only

Oxolamine (citrate)

CAT: 0804-HY-B1042-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B1042-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Oxolamine citrate (SKF-9976 citrate) is an orally active antitussive. Oxolamine citrate can inhibit CYP2B1/2. Oxolamine citrate has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine citrate increases the AUC of Warfarin and prolongs its terminal half-life. Oxolamine citrate can be used in respiratory disease research[1][2][3][4].
CAS Number
1949-20-8
Product Name Alternative
SKF-9976 citrate; AF-438 citrate
UNSPSC
12352005
Hazard Statement
H302
Target
Cytochrome P450
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Oxolamine-citrate.html
Purity
99.87
Solubility
DMSO : ≥ 100 mg/mL|H2O : 14.29 mg/mL (ultrasonic)
Smiles
CCN(CC)CCC1=NC(C2=CC=CC=C2)=NO1.O=C(CC(C(O)=O)(O)CC(O)=O)O
Molecular Formula
C20H27N3O8
Molecular Weight
437.44
Precautions
H302
References & Citations
[1]Kirilmaz L, et, al. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics. J Microencapsul. Apr-Jun 1992;9 (2) :167-72.|[2]GIUDICI G, et, al. [On the anti-inflammatory action of oxolamine citrate]. Minerva Med. 1961 Oct 31;52:3752-5.|[3]Zhu X, et al. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos. 2007 Apr;28 (3) :125-33. |[4]Dahlgren S, et al. The effect of oxolamine citrate on experimentally produced inflammation in the respiratory organs. Acta Pharmacol Toxicol (Copenh) . 1966;24 (2) :286-96.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CYP2